close

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.72
+3.44 (1.68%)
AAPL  272.99
+6.81 (2.56%)
AMD  210.80
+14.20 (7.22%)
BAC  50.23
-0.84 (-1.64%)
GOOG  310.46
-1.23 (-0.39%)
META  637.51
+0.26 (0.04%)
MSFT  386.14
+1.67 (0.43%)
NVDA  191.98
+0.43 (0.22%)
ORCL  144.58
+3.27 (2.31%)
TSLA  403.03
+3.20 (0.80%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today